High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

Cancer

Volumn 92, Issue 1, 2001, Pages 7-14

  Cortes, Jorge ^a,b   Estey, Elihu ^a   O'Brien, Susan ^a   Giles, Francis ^a   Shen, Yu ^a   Koller, Charles ^a   Beran, Miloslav ^a   Thomas, Deborah ^a   Keating, Michael ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 61 ^*  (United States)

Author keywords

Acute myeloid leukemia, liposomal daunorubicin, cytarabine, anthracyclines

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RECURRENT CANCER; RELAPSE; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DRUG CARRIERS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LIPOSOMES; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 0035396908     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010701)92:1<7::AID-CNCR1285>3.0.CO;2-D     Document Type: Article

References (32)

1. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors
2. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
3. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue
4. Liposomes as carriers of cancer chemotherapy. Current status and future prospects
5. Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity
6. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome)
7. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
8. 2 of liposomal encapsulated daunorubicin (DaunoXome)
9. Liposomal daunorubicin (DaunoXome) is cytotoxic to childhood acute lymphoblastic leukemia cells
10. Anthracycline efficacy in vitro: Cytotoxicity of liposomal/nonliposomal daunorubicin and doxorubicin for multiple tumor cell types
11. Phase I study of liposomal daunorubicin in patients with acute leukemia
12. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
13. Treatment of newly diagnosed AML and MDS with cyclophosphamide, Ara-C, Topotecan
14. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia
15. Treatment of refractory AML
16. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia
17. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemias patients treated with an intensive phase II protocol based on high induction dose of daunorubicin
18. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
19. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
20. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia
21. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Sowthwest Oncology Group (SWOG) study
22. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly
23. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study
24. Double induction strategy in AML comparing high with standard dose Ara-C: Hematotoxicity and antileukemic efficacy
25. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance
26. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
27. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA
28. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
29. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
30. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
31. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice
32. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion